Literature DB >> 16051953

Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy.

Michaël Lévy1, Christiane Copie-Bergman, Christine Gameiro, Marie-Thérèse Chaumette, Marie-Hélène Delfau-Larue, Corinne Haioun, Antoine Charachon, François Hemery, Philippe Gaulard, Karen Leroy, Jean-Charles Delchier.   

Abstract

PURPOSE: To determine the impact of translocation t(11;18) on response to oral alkylating agents in gastric mucosa-associated lymphoid tissue lymphoma (GML). PATIENTS AND METHODS: Fifty-three patients with a GML were studied. Helicobacter pylori-positive patients (n = 34) received anti-H pylori treatment and H pylori-negative patients (n = 19) or patients who failed to respond to anti-H pylori treatment received oral alkylating agents. t(11;18) was detected by reverse transcription polymerase chain reaction from frozen gastric biopsies.
RESULTS: t(11;18) was detected in 32% of patients. It was more prevalent in H pylori-negative as compared with H pylori-positive patients (12 of 19 v five of 34 patients; P = .0005). Among 31 H pylori-eradicated patients, t(11;18) was detected in three patients, all of whom experienced treatment failure, and it was absent in 28 patients: 21 patients (75%) were in remission and seven patients (25%) experienced treatment failure (P = .03). Among 21 patients who received an alkylating agent, t(11;18) was detected in 12 patients: five patients (42%) were in remission and seven patients (58%) experienced treatment failure. t(11;18) was absent in nine patients: eight patients (89%) were in remission and one patient (11%) experienced treatment failure by the end of treatment. Four patients in remission relapsed during follow-up (median, 7 years): they all had t(11;18). Durable remission was obtained in eight (89%) of the nine patients without t(11;18) versus one of the 12 patients (8%) with t(11;18) (P = .0003).
CONCLUSION: Presence of t(11;18) in GML is predictive of resistance to oral alkylating agents, with less than 10% of durable remission at long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051953     DOI: 10.1200/JCO.2005.05.660

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

Review 1.  Current status of gastric MALT lymphoma.

Authors:  T Wündisch; M Stolte
Journal:  Curr Gastroenterol Rep       Date:  2006-10

Review 2.  Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.

Authors:  Chris M Bacon; Ming-Qing Du; Ahmet Dogan
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

Review 3.  Effective management strategies for patients with marginal zone lymphoma.

Authors:  Cecilia B Rosand; Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Future Oncol       Date:  2017-12-20       Impact factor: 3.404

4.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

Review 5.  Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives?

Authors:  Lara M Kingeter; Brian C Schaefer
Journal:  Cell Signal       Date:  2009-09-19       Impact factor: 4.315

Review 6.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

7.  Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.

Authors:  Monika Joshi; Hassan Sheikh; Kamal Abbi; Sarah Long; Kamal Sharma; Mark Tulchinsky; Elliot Epner
Journal:  Ther Adv Hematol       Date:  2012-10

Review 8.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 9.  Clinical aspects of malt lymphomas.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Xanthi Yiakoumis; Sotirios Sachanas; Maria Moschogiannis; Pantelis Tsirkinidis; Penelope Korkolopoulou; Helen A Papadaki; Maria K Angelopoulou
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

10.  Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial.

Authors:  Barry W Hancock; Wendi Qian; David Linch; Jean-Charles Delchier; Paul Smith; Ira Jakupovic; Cathy Burton; Robert Souhami; Andrew Wotherspoon; Christiane Copie-Bergman; Carlo Capella; Catherine Traulle; Michael Levy; Sergio Cortelazzo; Andres J M Ferreri; Achille Ambrosetti; Graziella Pinotti; Giovanni Martinelli; Umberto Vitolo; Franco Cavalli; Christian Gisselbrecht; Emanuele Zucca
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.